High frequency of juxtamembrane domain ERBB2 mutation in gastric cancer
S Park, S Ahn, DG Kim, H Kim… - Cancer Genomics & …, 2022 - cgp.iiarjournals.org
Background/Aim: ERBB2 mutation is an emerging therapeutic target in solid tumors; its
therapeutic responses depend on the location of mutation. In gastric cancer, the profiles of …
therapeutic responses depend on the location of mutation. In gastric cancer, the profiles of …
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers
The oncogenic role ERBB2 amplification is well established in breast and gastric cancers.
This has led to the development of a well‐known portfolio of monoclonal antibodies and …
This has led to the development of a well‐known portfolio of monoclonal antibodies and …
[HTML][HTML] Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors
H Wang, J Miao, Y Wen, X Xia, Y Chen… - … & Oncology Research, 2022 - por-journal.com
ERBB2 abnormalities frequently occur and serve as rationale therapeutic targets in cancer.
In this study, clinical and next-generation sequencing data from 14,956 patients across more …
In this study, clinical and next-generation sequencing data from 14,956 patients across more …
Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
J Chmielecki, JS Ross, K Wang, GM Frampton… - The …, 2015 - academic.oup.com
Abstract Background. Targeted ERBB2/HER2 inhibitors are approved by the US Food and
Drug Administration for the treatment of breast, gastric, and esophageal cancers that …
Drug Administration for the treatment of breast, gastric, and esophageal cancers that …
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2
M Nagano, S Kohsaka, T Ueno, S Kojima, K Saka… - Clinical Cancer …, 2018 - AACR
Purpose: The advent of next-generation sequencing technologies has enabled the
identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) …
identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) …
[HTML][HTML] Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
JD Barros-Silva, D Leitao, L Afonso, J Vieira… - British journal of …, 2009 - nature.com
The clinical significance of ERBB2 amplification/overexpression in gastric cancer remains
unclear. In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using …
unclear. In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using …
[HTML][HTML] Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung
TJ Grob, I Kannengiesser, MC Tsourlakis… - Modern Pathology, 2012 - Elsevier
The HER2 protein, encoded by the ERBB2 gene, is a molecular target for the treatment of
breast and gastric cancer by monoclonal antibodies or tyrosine kinase inhibitors. While …
breast and gastric cancer by monoclonal antibodies or tyrosine kinase inhibitors. While …
Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive …
K Hino, T Nishina, T Kajiwara, H Bando… - JCO Precision …, 2022 - ascopubs.org
PURPOSE ERBB2 copy number (CN), measured using next-generation sequencing, is a
predictive biomarker for trastuzumab efficacy in human epidermal growth factor receptor 2 …
predictive biomarker for trastuzumab efficacy in human epidermal growth factor receptor 2 …
Mutational and expressional analysis of ERBB3 gene in common solid cancers
ERBB3 is a member of EGFR family receptor tyrosine kinases, genetic alterations of which
are common and therapeutically targeted in human cancers. Recently, somatic mutations of …
are common and therapeutically targeted in human cancers. Recently, somatic mutations of …
[CITATION][C] ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas
EG Jeong, YH Soung, JW Lee, SH Lee… - … journal of cancer, 2006 - Wiley Online Library
Dear Sir, Protein tyrosine kinases, which regulate cell signaling pathways mediating a
number of processes in cell survival and growth, comprise a large fraction of the dominant …
number of processes in cell survival and growth, comprise a large fraction of the dominant …